Background
==========

The size of the elderly population is growing rapidly worldwide, including developed and developing countries \[[@B1]\]. Older age is a risk factor for developing many diseases, including venous thromboembolic events (VTEE) and atrial fibrillation (AF). Thus, the disease burden associated with VTEE and AF is expected to expand as elderly populations continue to rise.

The impact of VTEE and AF on mortality and morbidity is substantial, as are the socioeconomic consequences in terms of hospital admissions and management of chronic diseases and disabilities. AF is the most common cardiac rhythm disorder, affecting approximately 2.3 million people in the United States (US) and 4.8 million in the 6 major pharmaceutical markets (France, Spain, Germany, United Kingdom, Italy, Japan,) combined \[[@B2]\]. VTEEs are common vascular diseases with an average annual incidence rate among in the US and Europe of 100 to 200 per 100,000 person-years in the US and Europe; roughly 900,000 incident or recurrent cases occurring annually in the US alone \[[@B3]-[@B6]\]. The incidence rate appears to be similar or higher among African-Americans and lower for Asian- and Native-American populations in the US \[[@B7],[@B8]\].

Although the epidemiology of VTEE and AF is very well described in North America and Europe, there is a paucity of published epidemiological data on the descriptive epidemiology of patients with these conditions in South American populations. Therefore, we conducted a descriptive study of patients diagnosed with VTEE and AF to better understand the disease burden in Venezuela.

Methods
=======

Using a retrospective cross-sectional study design, we reviewed medical records for two groups of adult (18+ years) patients (VTEE or AF) diagnosed between January 2000 and December 2005 at three private Venezuelan hospitals or clinics located in Caracas: Clínica Santa Sofía, Policlínica Metropolitana, and Hospital de Clínicas Caracas. Hospital de Clinicas Caracas, the most technologically advanced private health care institution in Venezuela with 13,500 admissions, 7,000 annual surgeries and 180 beds for inpatient population. The hospital provides primary, tertiary, and transplant services and employs 400 physicians and 373 nurses who provide excellent medical care services. Policlinica Metropolitana and Clinica Santa Sofia are another 2 private clinics that provide excellent medical services. Both clinics provide primary, tertiary and transplant services as well. All hospitals and clinics included in the study maintain a central repository of electronic medical records for all patients admitted through the emergency rooms. The diagnosis of VTEE or AF was defined using the International Classification of Disease 10^th^Revision (ICD- 10) and confirmed by the treating physician \[[@B9]\]. This research received a waiver of consent from the Independent Ethics Committee (\"Comisión de Bioética y Bioseguridad del Fondo Nacional de Ciencia y Tecnología\") in Venezuela for use of patient medical record data.

Data was abstracted from medical records using a structured case report form to gather information regarding age, gender, weight, source at index hospitalization, admission diagnosis, use of anticoagulation therapy, length of hospital stay and disposition, comorbidities (defined by ICD-10 codes) and medications (Venezuela\'s Vademecum). Vademecum is a medication handbook which contains information on trademarks, active principles, interactions, adverse reactions, international equivalences, and manufacturers. Descriptive statistics were calculated using SPSS V. 12 software.

Results
=======

The study population included 401 patients with VTEEs and 996 AF patients (Table [1](#T1){ref-type="table"}). The most common VTEEs were phlebitis or thrombophlebitis (67%), pulmonary embolism (17%), other venous embolism or thrombosis (9%), venous embolism combined with phlebitis (6%). The mean age at diagnosis was 60.1 and 70.7 years old for VTEE and AF patients, respectively. More VTEEs occurred among women (58%), whereas AF was more common in men (58%). Most patients presented at the emergency room (VTEE: 89%, AF: 87%) with mean hospitalization duration of approximately 5 days for both patient groups. The majority of patients experienced a single VTEE (88%) or AF (80%) event during the study period from 2000 to 2005. Most patients returned home following hospitalization; 5 VTEE and 4 AF patients readmitted to the hospital (data not shown). Comorbidities were generally more common among AF patients compared to patients diagnosed with a VTEE. Hypertension was the most common comorbidity observed in both VTEE (26%) and AF (54%) patients, followed by heart failure (VTEE: 3%, AF: 23%), diabetes (VTEE: 12%, AF: 12%) and congestive heart failure (VTEE: 3%, AF: 14%). Cancer more common among VTEE patients (8%) compared with AF patients (4%). In a subset of patients with anthropometric data available, mean height and weight were similar in both disease groups (data not shown).

###### 

Characteristics of patients diagnosed with a venous thromboembolic event (VTEE) or atrial fibrillation (AF), Venezuela, 2000-2005

  Characteristic                              VTEE (n = 401)   AF (n = 996)
  ------------------------------------------- ---------------- ---------------
  **Age (years)**, mean (range)               60.1 (22-103)    70.7 (18-101)
  **Sex, N (%)**                                               
   Male                                       168 (42%)        577 (58%)
   Female                                     230 (58%)        410 (42%)
  **No. VTEE/AF Events, 2000- 2005, N (%)**                    
   1                                          354 (88%)        798 (80%)
   2                                          37 (9%)          146 (15%)
   3                                          8 (2%)           35 (3%)
   4+                                         2 (\<1%)         17 (2%)
  **Hospital Admission Source, N (%)**                         
   Emergency room                             356 (89%)        865 (87%)
   Routine admission/outpatient               27 (7%)          76 (8%)
   Transfer                                   16 (4%)          51 (5%)
   Unknown                                    2 (\<1%)         4 (\<1%)
  **Days of Hospital Stay, mean (range)**     5.4 (1-75)       4.5 (1-49)
  **Comorbidities, N (%)**                                     
   Hypertension                               105 (26%)        540 (54%)
   Heart failure                              13 (3%)          225 (23%)
   Diabetes                                   46 (12%)         122 (12%)
   Congestive heart failure                   12 (3%)          134 (14%)
   Cancer                                     33 (8%)          35 (4%)
   Coronary artery disease                    4 (1%)           47 (5%)
   Prior myocardial infarction                2 (\<1%)         45 (5%)
   Prior transient ischemic attack            2 (\<1%)         37 (4%)
   Prior stroke                               4 (1%)           29 (3%)
   Prior bleeding event                       0                2 (\<1%)

Table [2](#T2){ref-type="table"} describes the primary hospital admission and discharge codes for the VTEE and AF patients. Deep vein thromboembolism was the most common hospital admission (41%) and discharge (53%) diagnosis for VTEE patients. Among AF patients, AF was listed as the admission diagnosis for only 44% of population; however, AF was recorded as the primary diagnosis for 86% of patients at the time of hospital discharge.

###### 

Common hospital admission and discharge diagnoses for patients with venous thromboembolic event (VTEE) and atrial fibrillation (AF) in Venezuela

                                                VTEE (n = 401)   AF (n = 996)         
  --------------------------------------------- ---------------- -------------- ----- -------
  **Admission diagnosis**                                                             
   Atrial fibrillation                          0                0.0%           439   44.1%
   Deep venous thromboembolism                  165              41.1%          0     0.0%
   Cerebrovascular accident                     6                1.5%           86    8.6%
   Cardiac insufficiency                        8                2.0%           60    6.0%
   Pulmonary embolism                           45               11.2%          0     0.0%
   Thrombophlebitis                             34               8.5%           0     0.0%
   Ischemic cardiopathy                         3                0.7%           27    2.7%
   Pneumonia                                    6                1.5%           21    2.1%
   Unstable angina                              0                0.0%           27    2.7%
   Respiratory infection                        4                1.0%           23    2.3%
   Hypertension                                 5                1.2%           22    2.2%
   Respiratory insufficiency                    12               3.0%           14    1.4%
   Cellulitis                                   25               6.2%           0     0.0%
   Embolism/thromb. of arteries lower extrem.   21               5.2%           0     0.0%
   Arrhythmia                                   0                0.0%           14    1.4%
   Syncope                                      0                0.0%           14    1.4%
   Pulmonary oedema                             0                0.0%           12    1.2%
   Acute coronary syndrome                      1                0.2%           11    1.1%
   Other                                        66               16.5%          226   22.7%
  **Discharge diagnosis**                                                             
   Atrial fibrillation                          0                0.0%           857   86.0%
   Deep venous thromboembolism                  212              52.9%          3     0.3%
   Pulmonary embolism                           64               16.0%          7     0.7%
   Thrombophlebitis                             47               11.7%          0     0.0%
   Cardiac insufficiency                        6                1.5%           38    3.8%
   Cerebrovascular accident                     4                1.0%           24    2.4%
   Venous embolism and thrombosis               23               5.7%           1     0.1%
   Ischemic cardiopathy                         5                1.2%           14    1.4%
   Auricular flutter                            0                0.0%           14    1.4%
   Other                                        40               10.0%          39    3.9%

As presented in Table [3](#T3){ref-type="table"}, enoxaparin and warfarin were the mostly commonly prescribed anticoagulant medications for both VTEE and AF, although a larger proportion of VTEE patients (66% and 68%, respectively) were prescribed these medications compared to AF patients (48% and 32%). Heparin was used more frequently among VTEE patients (40%) compared to those with AF (3%); roughly 3% of both patient groups were treated with dalteparin. The most common concomitant medications among the VTEE patients were proton-pump inhibitors (38%), H2 blockers (33%), and benzodiazepines (30%). A similar proportion of AF patients were treated with these same medications, but the majority was also treated with antiarrhythmic drugs (83%). Twenty (2%) of AF patients and 3 (\<1%) of VTEE patients died during the study period (data not shown).

###### 

Common medications prescribed for patients with a venous thromboembolic event (VTEE) or atrial fibrillation (AF)

                                                VTEE (n = 401)   AF (n = 996)         
  --------------------------------------------- ---------------- -------------- ----- -------
  **Anticoagulant used**                                                              
   Dalteparin sodium                            12               3.0%           24    2.4%
   Enoxaparin                                   264              65.8%          476   47.8%
   Heparin sodium                               159              39.7%          32    3.2%
   Warfarin sodium                              271              67.6%          323   32.4%
  **Class of Concomitant Medications**                                                
   Antiarrhythmic drugs                         38               9.5%           831   83.4%
   Proton-pump inhibitors                       151              37.7%          293   29.4%
   Benzodiazepines                              119              29.7%          312   31.3%
   H2 blockers                                  131              32.7%          239   24.0%
   Diuretics                                    22               5.5%           248   24.9%
   Antiplatelet drugs                           51               12.7%          188   18.9%
   Angiotensin-converting enzyme inhibitor      27               6.7%           208   20.9%
   Beta blockers                                25               6.2%           156   15.7%
   Aldosterone receptor antagonists             15               3.7%           141   14.2%
   Nonsteroidal anti-inflammatory medications   66               16.5%          73    7.3%
   Salicylates                                  17               4.2%           85    8.5%
   Quinolone antibiotics                        31               7.7%           54    5.4%
   Calcium antagonist                           9                2.2%           71    7.1%
   Cephalosporins                               44               11.0%          26    2.6%

Discussion
==========

This is one of the first studies describing the epidemiology of VTEE and AF in Venezuela. The frequency of some common and rare comorbid conditions in the Venezuelan patient population is similar to what has been observed in North American and European populations. For example, approximately one quarter of VTEE and half of all AF patients in the Venezuelan population were hypertensive; similar rates have been reported in the literature \[[@B10]-[@B14]\]. Rare events such as prior myocardial infarction, transient ischemic attack or stroke each occurred in roughly 0-5% of AF patients in the present study as well as other large cohorts \[[@B11],[@B12],[@B14]\]. The prevalence of heart failure and diabetes found in Venezuelan VTEE and AF populations also is similar to what has been reported in other published studies \[[@B10]-[@B15]\]. This new research suggests that Venezuelan patients with VTEE and AF share similar epidemiologic characteristics and risk factors for developing these conditions as populations in other parts of the world.

We found that the Venezuelan VTEE population was less likely to have cancer as a comorbidity (8%) compared to VTEE patients in the US and Europe which ranges from 20-32% \[[@B10],[@B15],[@B16]\]. It is estimated that cancer accounts for approximately 20% of incident VTEE in the US and the risk is highest for patients diagnosed with certain types of cancer or receiving particular therapies such as immunosuppressive or cytotoxic chemotherapy \[[@B3]\]. It is possible that the lower cancer prevalence in Venezuelans with VTEE is explained by reduced access to expensive or experimental cancer treatments or differences in incidence rates of cancers such as digestive malignancies that are more closely associated with VTEE \[[@B3],[@B17]\].

There are several strengths to this cross-sectional study. First, the retrospective study included the use of ICD-10 diagnosis codes and Vademecum medication codes which provide consistent patient data. The use of ICD codes has been shown to reliably capture cardiovascular and cerebrovascular events \[[@B18],[@B19]\]. For example, defining patient-level covariates by the ICD-10 diagnoses are quite good and coded with high sensitivity for coronary artery disease/ischemic heart disease (98%), diabetes mellitus (99%), history of cerebrovascular accident (95%), hypertension (83%), and TIA (79%) \[[@B20],[@B21]\]. Further, we studied data from the major private hospitals or clinics serving the Caracas population.

This study has several limitations. As with most studies based on medical record data, this study was limited by the information recorded in the physicians\' notes. We did not validate the data about the sensitivity or specificity of the ICD-10 codes used to identify VTEE or AF patients. Additionally, no other standard clinical criteria or definitions beyond ICD-10 codes were used to define the VTEE or AF events. Thus, the completeness of the captured VTEE or AF events is unclear. However, the ICD-10 classification system includes distinct codes for the diseases of interest, reducing the likelihood of misclassification. Previous studies have reported high sensitivity associated with ICD-10 discharge codes for PE (89%) and AF (98%); the sensitivity for DVT diagnoses is lower (58%) \[[@B22],[@B20]\]. It is unclear whether the patients from the three hospitals and clinics are representative of the overall population in Venezuela. For example, these clinics may represent a higher socioeconomic bracket than the average for Venezuela. This study does not include an internal comparison group to determine whether the characteristics of VTEE or AF patients significantly differ from the general population.

Little is known about VTEE or AF in regions outside the United States or Europe. This study provides a starting point for additional future analyses of these diseases in South American populations. Accurately assessing the region-specific disease burden, patient characteristics and treatment patterns is essential for understanding the unmet needs and improving public health.

Conclusions
===========

In conclusion, the study provides evidence that Venezuelan patients diagnosed with VTEE and AF events are similar with regard to epidemiological and clinical factors as North American and European patients.
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